Zentiva AG, a fully-owned subsidiary of Zentiva Pharma GmbH based in Frankfurt am Main, Germany, and part of the Zentiva group, has completed its voluntary public tender for the acquisition of shares in APONTIS PHARMA AG (APONTIS PHARMA).
Following the acquisition’s completion, Zentiva now controls approximately 83.57% of APONTIS PHARMA’s share capital and around 85.27% of its voting rights. As disclosed on November 27, 2024, all stipulations detailed in the offer document have been either met or preemptively waived by Zentiva. Settlement for the purchase offer was finalized on December 9.
Under the investment agreement between the two companies, APONTIS PHARMA’s management board has agreed, insofar as legally justifiable and aligned with their fiduciary obligations, to withdraw APONTIS PHARMA shares from public market trading (Freiverkehr) subsequent to the offer’s settlement. An independent delisting proposal will not be necessary.
The timeframe for Zentiva’s voluntary public purchase offer towards APONTIS PHARMA shareholders has concluded. Shareholders eager to sell their shares can reach out via email to [email protected].
Zentiva operates as a Pan-European platform specializing in the development, manufacturing, and distribution of high-quality, cost-effective medicines to over 100 million individuals across Europe. The company boasts four fully-owned production facilities and a comprehensive network of external manufacturing collaborations to ensure reliable supply. Zentiva provides solutions in critical therapeutic sectors such as cardiology, diabetes, oncology, respiratory, and CNS while expanding its self-care product range.
APONTIS PHARMA is a prominent pharmaceutical enterprise in Germany, famed for its single-pill combination products. These pills integrate two to three generic active compounds into a one-a-day dosage form. Scientific studies confirm that single-pill therapies significantly enhance patient adherence, improving treatment outcomes and life quality while decreasing complications, mortality, and healthcare expenses.